Literature DB >> 26918911

Treatment Outcomes and Prognostic Factors of Selective Laser Trabeculoplasty for Open-angle Glaucoma Receiving Maximal-tolerable Medical Therapy.

Atsuya Miki1, Rumi Kawashima, Shinichi Usui, Kenji Matsushita, Kohji Nishida.   

Abstract

PURPOSE: To evaluate the efficacy of selective laser trabeculoplasty (SLT) for patients with open-angle glaucoma receiving maximal-tolerable medical therapy. PATIENTS AND METHODS: Consecutive patients with open-angle glaucoma who were followed up for at least 1 year after SLT were retrospectively evaluated. The effectiveness was assessed using Kaplan-Meier survival analysis with 2 criteria for failure: (1) intraocular pressure (IOP) equal to or more than baseline; and (2) <20% reduction from baseline, on 2 consecutive visits. Those 2 failure criteria also included loss of light perception, reoperation of SLT, and glaucoma surgery. Influence of baseline factors on success were assessed using mixed-effects Cox proportional hazard models.
RESULTS: Seventy-five eyes [39 primary open-angle glaucoma, 23 exfoliation glaucoma, and 13 secondary open-angle glaucoma (SOAG)] of 59 patients (21 females) aged 65.5±15.9 (mean±SD) were included. Preoperative mean IOP was 23.3±6.5 mm Hg with 3.4±1.3 IOP lowering medications. The overall success ratio at the end of study period was 45.3% by criterion 1 and 14.2% by criterion 2. The success ratio by criterion 1 and 2 was 61.1% and 21.7% in primary open-angle glaucoma, 29.3% and 14.5% in exfoliation glaucoma, and 15.4% and 7.7% in SOAG, respectively. Higher preoperative IOP and diagnosis of SOAG were significantly associated with treatment failure (P<0.01 and 0.04, respectively).
CONCLUSIONS: One-year efficacy of SLT in controlling IOP was very limited in patients with maximal-tolerable medical therapy. Types of glaucoma and preoperative IOP were significant prognostic factors for treatment success.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26918911     DOI: 10.1097/IJG.0000000000000411

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  8 in total

Review 1.  Selective laser trabeculoplasty: past, present, and future.

Authors:  A Garg; G Gazzard
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

Review 2.  Long-term results of micropulse laser trabeculoplasty with 577-nm yellow wavelength in patients with uncontrolled primary open-angle glaucoma and pseudoexfoliation glaucoma.

Authors:  Sevda Aydin Kurna; Ayse Demirciler Sonmez; Murat Yamic; Ahmet Altun
Journal:  Lasers Med Sci       Date:  2022-03-30       Impact factor: 2.555

3.  Outcome After Selective Laser Trabeculoplasty for Glaucoma Treatment in a Thai Population.

Authors:  Panrapee Funarunart; Isaraporn Treesit
Journal:  Clin Ophthalmol       Date:  2021-03-18

Review 4.  A Review of Selective Laser Trabeculoplasty: Recent Findings and Current Perspectives.

Authors:  Yujia Zhou; Ahmad A Aref
Journal:  Ophthalmol Ther       Date:  2017-03-03

5.  Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma.

Authors:  Taro Baba; Kazuyuki Hirooka; Hiroki Nii; Yoshiaki Kiuchi
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

6.  Selective Laser Trabeculoplasty for Medically Uncontrolled Pseudoexfoliation Glaucoma in Korean Patients.

Authors:  Jung Hyun Lee; Jung Hwa Na; Hye Jin Chung; Jin Young Choi; Mi Jeung Kim
Journal:  Korean J Ophthalmol       Date:  2021-10-12

7.  Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty.

Authors:  Corine Ghosn; Lakshmi Rajagopalan; Sveti Ugarte; Shruti Mistry; Werhner Orilla; Margot L Goodkin; Michael R Robinson; Michael Engles; Mohammed Dibas
Journal:  J Ocul Pharmacol Ther       Date:  2022-04-18       Impact factor: 2.850

Review 8.  Energy Dose-Response in Selective Laser Trabeculoplasty: A Review.

Authors:  Nathan Radcliffe; Gus Gazzard; Thomas Samuelson; Peng Khaw; Xinghuai Sun; Tin Aung; Dennis Lam; Kuldev Singh; L Jay Katz; Michael Aronov; Zachary Sacks; Yoram Solberg; Richard Lindstrom; Michael Belkin
Journal:  J Glaucoma       Date:  2022-06-15       Impact factor: 2.290

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.